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Background: Previous studies have suggested that plasma ﬁbrinogen contributes to tumor cell prolifer-
ation, progression and metastasis. The current study was performed to evaluate the prognostic relevance
of preoperative plasma ﬁbrinogen in breast cancer patients.
Method: Data of 2073 consecutive breast cancer patients, who underwent surgery between January 2002
and December 2008 at the Sun Yat-sen University Cancer Center, were retrospectively evaluated. Plasma
ﬁbrinogen levels were routinely measured before surgeries. Participants were grouped by the cutoff
value estimated by the receiver operating characteristic (ROC) curve analysis. Overall survival (OS) was
assessed using KaplaneMeier analysis, and multivariate Cox proportional hazards regression model was
performed to evaluate the independent prognostic value of plasma ﬁbrinogen level.
Results: The optimal cutoff value of preoperative plasma ﬁbrinogen was determined to be 2.83 g/L. The
KaplaneMeier analysis showed that patients with high ﬁbrinogen levels had shorter OS than patients
with low ﬁbrinogen levels (p < 0.001). Multivariate analysis suggested preoperative plasma ﬁbrinogen as
an independent prognostic factor for OS in breast cancer patients (HR ¼ 1.475, 95% conﬁdence interval
(CI): 1.177e1.848, p ¼ 0.001). Subgroup analyses revealed that plasma ﬁbrinogen level was an unfa-
vorable prognostic parameter in stage IIeIII, Luminal subtypes and triple-negative breast cancer patients.
Conclusion: Elevated preoperative plasma ﬁbrinogen was independently associated with poor prognosis
in breast cancer patients and may serve as a valuable parameter for risk assessment in breast cancer
patients.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast cancer is by far the most common cancer and the main
cause of cancer death in women worldwide. According to the Na-
tional Cancer Institute, there were more than 230,000 cases of fe-
male breast cancer in 2014, and more than 40,000 women have
died of breast cancer [1]. The prognosis of breast cancer patients is
inﬂuenced by numerous factors, such as TNM staging, intrinsic
subtypes, age, and gender [2,3]. Recurrence and metastasis remainLtd. This is an open access article ua great challenge for cure despite the excellent outcomes of early-
stage breast cancer after standard treatments [4].
Recently, much attention has been given to the association be-
tween hypercoagulation and the progression of malignancies.
Increasing data indicated that the members of the coagulation
cascade are activated during cancer progression, and associated
with tumor stage, response to chemotherapy and prognosis [5].
Fibrinogen is one of the important indicators of coagulation. It is a
340-kDa glycoprotein mainly synthesized by hepatocytes and
converted to insoluble ﬁbrin by activated thrombin [6,7].
Fibrinogen is involved in a number of biological processes that
are regulated by different cytokines, such as vascular endothelial
growth factor (VEGF), interleukin-1 (IL-1) beta, and ﬁbroblastnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Flow chart of the patient selection.
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strated that an increased level of plasma ﬁbrinogen is frequently
observed in cancer patients and that ﬁbrinogen plays a vital role in
tumorigenesis and progression, including stroma formation,
angiogenesis, and hematogenous metastasis [11,12]. Elevated level
of preoperative plasma ﬁbrinogen has been associated with poor
prognosis in patients with malignancies, such as lung cancer
[13,14], colorectal cancer [15,16], pancreatic cancer [17], prostate
cancer [18] and renal cell carcinoma [19].
However, few studies have evaluated the signiﬁcance of pre-
operative plasma ﬁbrinogen level in breast cancer patients as a
predictor of survival after surgical treatment. The aim of this
retrospective clinical study was to investigate the association be-
tween the plasma ﬁbrinogen level and the prognosis of breast
cancer patients.
Materials and methods
Study population
Patients with histologically diagnosed of breast cancer between
January 2002 and December 2008 in the Sun Yat-sen University
Cancer Center (SYSUCC) were retrospectively reviewed. Other in-
clusion criteria were as follows: (1) received surgical treatment and
(2) female patients. Exclusion criteria were as follows: (1) received
neoadjuvant chemotherapy before surgery; (2) received surgical
treatment before admission; (3) with previous or coexisting can-
cers other than breast cancer; (4) conﬁrmed metastasis; (5)
concomitant conditions inﬂuencing plasma ﬁbrinogen level, such
as liver disease, blood coagulation disorders and daily antiplatelet
or anticoagulant treatment before surgery; (6) not enough data can
be extracted. All patients were followed up to December 31, 2014 or
until death from any cause.
Clinical data collection
Baseline characteristics including age, menstrual status, patho-
logical diagnosis, histologic grade, axillary lymph node status,
hormone receptor and human epidermal growth factor receptor-2
(HER-2) status, surgery type, family history, date of last follow-up
or death and preoperative plasma ﬁbrinogen level were collected.
Fibrinogen levels were measured as part of the routine clinical
evaluation prior to surgery by the Clauss method using Dade
Thrombin Reagent™ and a Sysmex CA-7000 automated coagul-
ometer (Sysmex, Kobe, Japan). Plasma ﬁbrinogen levels between
1.80 and 4.00 g/L were considered to be normal. The clinical stages
of the disease were determined by TNM staging system according
to the AJCC, and the cancer subtypes were classiﬁed as follows:
Luminal A subtype (estrogen receptor positive (ERþ) and proges-
terone receptor positive (PRþ), HER-2), luminal B subtype (ERþ
and/or PRþ, HER-2þ), HER-2 overexpressing subtype (ER, PR,
HER-2þ) and triple-negative subtype (ER, PR, HER-2). The
follow-up of patients was performed through outpatient medical
records, telephone or letters by the “Department of Follow-up &
Medical Record Management”.
Statistical analyses
Preoperative plasma ﬁbrinogen values were expressed using
mean and standard deviations (SD), and categorical data were
described using numbers and percentages. KolmogoroveSmirnov
test was performed to test the normal distribution of the data. The
correlation between patients' characteristics and preoperative
plasma ﬁbrinogen was evaluated by unpaired t-test or one-way
analysis of variance (ANOVA), and differences between categorieswere examined using the Chi-squared test. The endpoint assessed
was overall survival (OS), calculated from the time of pathological
diagnosis to date of death from any cause or the last follow-up. SPSS
19.0 (SPSS Inc., Chicago, IL, USA) was used to perform all statistical
analyses in the present study. The clinical signiﬁcance and the
cutoff value for the continuously coded variable preoperative
plasma ﬁbrinogen level were determined by the ROC curve anal-
ysis, and patients were categorized into two groups according to
the cutoff value to assess the risk of death. KaplaneMeier method
was carried out for survival analyses and the differences between
the groups were assessed by log-rank test. Factors examined in the
univariate analysis were age (35 vs. >35 years), menstrual status,
tumor type, histologic grade, tumor size, lymph node status, hor-
mone receptor status, HER-2 status, surgical method, family history
and plasma ﬁbrinogen level. Univariate and multivariate analyses
(Cox proportional hazards model) were performed to identify the
independent variables associated with OS. Hazard ratios (HRs) and
the corresponding 95% conﬁdence intervals (CIs) estimated from
the Cox analysis were regarded as relative risks, and a two-tailed p
value < 0.05 was considered signiﬁcant.
Results
Patient characteristics
A total of 2073 consecutive patients with histopathologically
diagnosed breast cancer in SYSUCC were enrolled after eligibility
review. The selection process is shown in Fig. 1. The median follow-
up time was 75 months (range 3e143 months), and death occurred
in 329 (15.9%) of the 2073 breast cancer patients. Themedian age of
the enrolled patients was 49.0 years (range: 22e96 years), and 189
(9.1%) patients were aged below 35 years. Patient characteristics
and correlations between preoperative plasma ﬁbrinogen level and
clinicopathological parameters are shown in Table 1. The mean
level of preoperative plasma ﬁbrinogen level was 2.88 ± 0.68 g/L,
and it was associatedwith age andmenstrual status (both p< 0.001,
Table 1). Middle-aged and elderly (>35 years old) and post-
menopausal patients had higher preoperative plasma ﬁbrinogen
level. No correlation was observed between ﬁbrinogen level and
histologic grades, tumor size, lymph node status, hormone receptor
status, HER-2 status and family history (all p > 0.05). Moreover,
patients who experienced poor outcome had signiﬁcantly
increased preoperative ﬁbrinogen level compared to patients with
better prognosis (p < 0.001).
Cutoff value of preoperative plasma ﬁbrinogen
ROC curve analysis was performed to determine the optimal
cutoff value of preoperative plasma ﬁbrinogen level. The area under
Table 1
Clinicopathological parameters of breast cancer patients in the study cohort (n ¼ 2073).
Factor Fibrinogen (g/L) Patients, n (%)
Patients, n (%) Mean ± SD pa Low-ﬁbrinogen (<2.83 g/L) High-ﬁbrinogen (2.83 g/L) pb
Age <0.001 <0.001
35 189 (9.1) 2.66 ± 0.62 128 (11.7) 61 (6.2)
>35 1884 (90.9) 2.90 ± 0.68 962 (88.3) 922 (93.8)
Menopause <0.001 <0.001
Yes 529 (25.5) 3.10 ± 0.73 211 (19.4) 318 (32.3)
No 1544 (74.5) 2.80 ± 0.65 879 (80.6) 665 (67.6)
Tumor type 0.434 0.052
IDC 1913 (92.3) 2.88 ± 0.69 1064 (97.6) 945 (96.1)
ILC 59 (7.7) 2.95 ± 0.60 26 (2.4) 38 (3.9)
Histologic grade 0.090 0.130
G1 618 (29.8) 2.93 ± 0.66 313 (28.7) 321 (32.7)
G2 906 (43.7) 2.85 ± 0.67 491 (45.0) 409 (41.6)
G3 549 (26.5) 2.89 ± 0.74 286 (26.2) 253 (25.7)
Tumor size 0.181 0.365
T1 898 (43.3) 2.88 ± 0.69 480 (44.0) 418 (42.5)
T2 1075 (51.9) 2.86 ± 0.67 564 (51.7) 511 (52.0)
T3 100 (4.8) 2.99 ± 0.70 46 (4.2) 54 (5.5)
Lymph node status 0.560 0.003
N0 992 (47.9) 2.87 ± 0.69 531 (48.7) 461 (46.9)
N1 558 (26.9) 2.83 ± 0.68 317 (29.1) 241 (24.5)
N2 310 (15.0) 2.90 ± 0.64 149 (13.7) 161 (16.4)
N3 213 (10.2) 2.97 ± 0.75 93 (8.5) 120 (12.2)
ER 0.348 0.820
Positive 1317 (63.5) 2.86 ± 0.69 690 (63.6) 627 (63.8)
Negative 756 (36.5) 2.89 ± 0.67 400 (36.7) 356 (36.2)
PR 0.469 0.426
Positive 1429 (68.9) 2.87 ± 0.69 743 (31.8) 686 (69.8)
Negative 644 (31.1) 2.89 ± 0.67 347 (31.8) 297 (30.2)
HER-2 0.929 0.238
Positive 1571 (78.1) 2.88 ± 0.71 248 (23.5) 207 (21.3)
Negative 455 (21.9) 2.88 ± 0.68 807 (76.5) 764 (78.7)
Surgery 0.061 0.001
Modiﬁed radical mastectomy 1938 (93.5) 2.89 ± 0.69 1025 (94.0) 859 (90.9)
Breast conserving surgery 135 (6.5) 2.64 ± 0.60 65 (6.0) 124 (12.6)
Family history 0.327 0.267
Breast or ovarian carcinoma 38 (1.8) 2.89 ± 0.67 18 (1.8) 20 (2.0)
Other carcinomas 90 (4.4) 2.88 ± 0.65 44 (4.2) 46 (4.5)
No 1945 (93.8) 2.86 ± 0.67 987 (94.0) 958 (93.5)
Overall survival <0.001 <0.001
Alive 1744 (84.1) 2.84 ± 0.66 961 (88.2) 783 (79.7)
Death 329 (15.9) 3.08 ± 0.78 129 (11.8) 200 (20.3)
Abbreviation: IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor-
2.
a Using t test or ANOVA, P < 0.05 was considered statistically signiﬁcant.
b Using Chi-squared test, P < 0.05 was considered statistically signiﬁcant.
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cutoff point for preoperative plasma ﬁbrinogen was 2.83 g/L with
the highest Youden's index. The breast cancer patients enrolled
were classiﬁed into two groups (low and high) according to the
plasma ﬁbrinogen concentration. A total of 1090 (52.6%) patients
were categorized as low-ﬁbrinogen group, while the remaining 983
(47.4%) patients as high-ﬁbrinogen group. The chi-squared test
indicated that, compared with the low-ﬁbrinogen group, patients
in the high-ﬁbrinogen group suffered more axillary lymph node
metastases and worse outcome (p ¼ 0.003 and < 0.001,
respectively).
Association of preoperative plasma ﬁbrinogen with survival
The 10-year OS rate was 78.0% for all 2073 patients, and the
mean survival time was 124.9 (95%CI: 123.0e126.8) months. The
KaplaneMeier curve indicated that patients in the high-ﬁbrinogen
group had worse OS rate than those in the low-ﬁbrinogen group
(mean survival time: 120.4 vs. 128.7 months, P < 0.001; Fig. 3).
In breast cancer patients, the preoperative plasma ﬁbrinogen
level was found to be associated with OS, alongwith other variablessuch as age, menstrual status, histologic grade, tumor size, lymph
node status, hormone receptor status, HER-2 status and surgical
methods, in the univariate analysis (Table 2, all p < 0.05). However,
preoperative plasma ﬁbrinogen was identiﬁed as an independent
prognostic factor for OS in the multivariate analysis using the Cox
proportional hazard model (HR ¼ 1.475, 95%CI: 1.177e1.848,
p ¼ 0.001). Reduction in duration of survival in breast cancer pa-
tients is associated with elevated preoperative plasma ﬁbrinogen
levels. In addition, menstrual status, tumor size (T3), lymph node
status, ER, and HER-2 were independent prognostic factors for OS.
Multivariate analysis stratiﬁed by clinical stages demonstrated
that the elevated preoperative plasma ﬁbrinogen level was signif-
icantly associated with worse OS in stage IIeIII breast cancer pa-
tients (HR ¼ 1.610 and 1.598, respectively, both p < 0.05, Table 3),
and the clinical outcome of stage I patients with elevated ﬁbrinogen
level was not signiﬁcantly different from those with low ﬁbrinogen
level (p ¼ 0.659). Meanwhile, the preoperative ﬁbrinogen level was
indicated as a risk factor for patients with breast cancer of Luminal
A, Luminal B, and triple negative subtypes (all p< 0.05, Table 3), and
there was a trend in HER-2 overexpressed subtype, but the signif-
icance could not be proven (p ¼ 0.287).
Fig. 2. ROC curve assessing the cutoff value of preoperative plasma ﬁbrinogen level for
predicting the overall survival (OS) in the cohort study. ROC: receiver operating
characteristic; AUC: area under the curve.
Fig. 3. KaplaneMeier curve estimates the overall survival (OS) of breast cancer pa-
tients according to the preoperative plasma ﬁbrinogen level in overall study cohort.
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Elevated preoperative plasma ﬁbrinogen level has been
determined to be an unfavorable prognostic factor in some ma-
lignancies, such as digestive system neoplasms [15e17], gyne-
cologic neoplasms [20], urologic neoplasms [21] and soft-tissue
sarcoma [22]. Recent studies had shown that ﬁbrinogen levels
were associated with disease development, metastasis and poor
prognosis.In the present study, the survival condition of 2073 breast
cancer patients was retrospectively analyzed and the association
between preoperative plasma ﬁbrinogen levels and the clinical
outcome in breast cancer patients was examined. The main ﬁnd-
ings of this study are as follows: (1) preoperative plasma ﬁbrinogen
level is an independent prognostic factor in breast cancer patients;
(2) elevated ﬁbrinogen levels are associated with poor clinical
outcome in patients with breast cancer of Luminal A, Luminal B and
triple negative subtypes.
The cutoff value of ﬁbrinogen in the present study was 2.83 g/L
and the patients enrolled were categorized into low- or high-
ﬁbrinogen groups. Compared with the low-ﬁbrinogen group, the
mean survival time of the high-ﬁbrinogen group was shorter (120.4
vs. 128.7 months, p < 0.001), and the overall 10-year survival rates
were 83.6% and 72.7% (p < 0.001), respectively, in both groups.
Patients with elevated plasma ﬁbrinogen (>2.83 g/L) levels had
1.475 times the risk of death in those with low ﬁbrinogen levels.
Tumor progression is the consequence of complex interactions
between tumor cells and the host environment and inﬂammatory
response [23]. The metastatic cancer cells leave the primary tumor
site, migrate and circulate through the bloodstream, adhere to the
vasculature of the target organ, invade the surrounding tissue and
establish a blood supply at the new metastatic site [24e26]. The
clotted plasma and platelets collectively stabilize the circulating
cancer cells by thrombus formation, thereby facilitating the
attachment and spread of these cells in the vasculature of the
distant target organs.
Fibrinogen is one of the important coagulative factors and sys-
temic inﬂammatory markers detected in the plasma; it enhances
the progression and invasive potential of tumor cells through
several possible mechanisms. Fibrinogen is deposited around solid
tumors and it provides a stable framework to the tumor extracel-
lular matrix. It also serves as a scaffold to support binding of growth
factors, such as ﬁbroblast growth factor-2 (FGF-2) and vascular
endothelial growth factor (VEGF), to tumor cells, and thus promotes
tumor proliferation and stimulates angiogenesis [11,27,28]. More-
over, plasma ﬁbrinogen and tumor cells interact with each other. A
large number of ﬁbrinogen receptors such as intercellular adhesion
molecule 1 (ICAM-1) and a5b1 integrin are present on the tumor
cell surface; thus, ﬁbrinogen acts as a bridging factor between the
tumor and host cells and enhances the endothelial adhesion of
tumor cell emboli in the vasculature of target organs, leading to the
occurrence of metastasis [29]. The release of tumor cells from the
primary tumor into the cardiovascular system is the initial step of
metastasis [26]. Fibrinogen promotes b3-integrin-mediated adhe-
sion of tumor cells to platelets, and the plateletetumor cell ag-
gregates thus formed could shield tumor cells from the innate
immune response, thereby leading to an increase in the number of
metastatic cells [30e32]. Previous study revealed that pulmonary
metastases were markedly reduced in ﬁbrinogen-deﬁcient mice
after intravenous injection of cancer cells, demonstrating the vital
role of ﬁbrinogen in the process of metastasis [33]. Furthermore,
anticoagulants, such as warfarin and heparin, have antitumor and
antimetastatic effects in vivo and in vitro [34,35].
Plasma ﬁbrinogen, an acute-phase protein, is found to be at an
elevated level during malignancy or systemic inﬂammation [36].
The high ﬁbrinogen level in cancer patients may be associated with
the tumor-derived humoral factors, such as macrophage colony-
stimulating factor, IL-1, and IL-6 [37e39]. In addition, previous
studies have shown that several procoagulant factors were syn-
thesized and overexpressed in tumor cells [40], and high levels of
ﬁbrinogen could also be endogenously synthesized by the epithe-
lial tumor cells.
Due to the retrospective nature of the current study, some
limitations exist. First, a selection bias cannot be excluded even
Table 2
Univariate and multivariate analyses of preoperative plasma ﬁbrinogen for OS in breast cancer patients.
Variable Univariate analysis Multivariate analysis
HR (95%CI) P value HR (95%CI) P value
Age 1.011 (1.001e1.021) 0.036 1.372 (0.957e1.965) 0.084
Menstrual status 0.725 (0.575e0.915) 0.007 0.711 (0.559e0.904) 0.005
Tumor type 0.808 (0.555e1.175) 0.265 0.618 (0.287e1.327) 0.216
Histologic grade
G1 1 (reference) 1 (reference)
G2 0.738 (0.564e0.967) 0.028 0.823 (0.622e1.087) 0.174
G3 1.300 (0.997e1.697) 0.053 1.070 (0.813e1.406) 0.636
Tumor size
T1 1 (reference) 1 (reference)
T2 1.533 (1.222e1.975) <0.001 1.157 (0.906e1.478) 0.2443
T3 3.970 (2.747e5.736) <0.001 2.019 (1.372e2.970) <0.001
Lymph node status
N0 1 (reference) 1 (reference)
N1 2.041 (1.487e2.800) <0.001 2.097 (1.526e2.881) <0.001
N2 3.747 (2.723e5.155) <0.001 3.588 (2.594e4.964) <0.001
N3 8.328 (6.144e11.288) <0.001 6.753 (4.922e9.266) <0.001
ER 0.543 (0.437e0.673) <0.001 0.646 (0.496e0.841) <0.001
PR 0.594 (0.477e0.740) <0.001 0.882 (0.681e1.142) 0.346
HER-2 2.028 (1.615e2.546) <0.001 1.380 (1.070e1.849) 0.001
Surgical method 0.321 (0.152e0.680) 0.003 0.524 (0.240e1.123) 0.101
Family history
No 1 (reference) 1 (reference)
BC or OC 1.121 (0.876e1.434) 0.363 1.078 (0.829e1.404) 0.574
Other carcinomas 1.100 (0.792e1.527) 0.570 1.042 (0.832e1.305) 0.720
Plasma ﬁbrinogen 1.445 (1.261e1.657) <0.001 1.475 (1.177e1.848) 0.001
Abbreviation: OS overall survival, HR hazard ratio, CI conﬁdence interval, ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor-2, BC
breast carcinoma, OC ovarian carcinoma.
Table 3
Prognostic impact of preoperative plasma ﬁbrinogen in various clinical stages and intrinsic subtypes.
Subgroup Univariate analysis Multivariate analysis
HR(95%CI) P value HR(95%CI) P value
Clinical stagesa
I 1.061(0.476e2.363) 0.886 1.208(0.522e2.795) 0.659
II 1.643(1.151e2.347) 0.006 1.610(1.119e2.318) 0.010
III 1.615(1.191e2.189) 0.002 1.598(1.163e2.194) 0.004
Intrinsic subtypesb
Luminal A 1.913(1.212e3.018) 0.005 2.060(1.275e3.329) 0.003
Luminal B 1.706(1.211e2.403) 0.002 1.455(1.014e2.087) 0.042
HER-2 overexpressed 1.620(0.965e2.719) 0.068 1.362(0.771e2.403) 0.287
Triple-negative 2.866(1.485e5.533) 0.002 2.379(1.188e4.762) 0.014
a Tumor size and lymph node status were not involved in the multivariate analyses.
b Hormone receptor status and HER-2 status were not involved in the multivariate analyses.
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were performed to minimize the bias. Second, high ﬁbrinogen
levels may be associated with a higher risk of thromboembolism
events in cancer patients, which may inﬂuence patients' survival,
and not enough data can be extracted due to the low occurrence (3/
2073) in the present study cohort. Moreover, the enrolled patients
underwent surgical treatment by multiple surgeons.
In conclusion, it was the ﬁrst report demonstrating that pre-
operative plasma ﬁbrinogen level was an independent prognostic
factor in breast cancer patients who underwent surgical treatment.
This parameter may help clinicians assess the risks of metastasis
and death in breast cancer patients. Further prospective trials are
needed to conﬁrm its prognostic signiﬁcance.Ethics statement
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